Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Nemtabrutinib (ARQ531; ARQ-531; MK-1026) is a novel, potent, orally bioavailable, and reversible / non-covalent BTK (Bruton's Tyrosine Kinase) inhibitor with potential antitumor activity. It inhibits WT-BTK and C481S-BTK with IC50s of 0.85 nM and 0.39 nM, respectively.
ln Vitro |
In the TMD8 cell line, ARQ 531 exhibits significant target inhibition. The IC50 values of WT-BTK and C481S-BTK in biochemical experiments were 0.85 nM and 0.39 nM, respectively. Furthermore, ARQ 531 also has significant inhibitory effects on TEK kinase, as demonstrated by IC50 values of 3.6.4 nM (TXK), 5.80 nM (TEC), and 5.23 nM (BMX). 3.86 nM (LCK), 4.22 nM (YES), 9.71 nM (BLK), 18.3 nM (HCK), 18.8 nM (LYNa), 25.9 nM (FGR), 32.2 nM (FYN), 48.0 nM (FRK) and TRK kinases 11.7 nM (TrkB), 13.1 nM (TrkA), and 19.1 nM (TrkC) are the IC50 of ARQ 531 against SRC kinase. ARQ 531 effectively suppresses the growth of several cell lines (TMD8: GI50=0.13 μM, REC1: GI50=0.18 nM) and is effective against cell lines that are dependent on the PI3K/AKT pathway, Src family kinases, and BCR.
|
---|---|
ln Vivo |
ARQ 531 works well in tumor xenograft models, such as TMD-8. After 14 days, ARQ 531 therapy completely reduced the tumor. In models of arthritis caused by collagen, ARQ 531 is also beneficial. In animal studies, ARQ 531 shown strong efficacy against arthritis. ARQ 531 demonstrated remarkable anticancer efficacy and long-lasting effects in a TMD8 xenograft mouse model driven by BTK. In a mouse model of collagen-induced arthritis (CIA), ARQ 531 showed in vivo effectiveness [1].
|
References |
[1]. S Eathiraj, et al. Targeting PCI-32765-Resistant BTK-C481S Mutation with ARQ 531, a Reversible Non-Covalent Inhibitor of BTK. Clinical Lymphoma Myeloma & Leukemia, 2016, 16: S47-S48
|
Molecular Formula |
C25H23CLN4O4
|
---|---|
Molecular Weight |
478.927524805069
|
CAS # |
2095393-15-8
|
SMILES |
O=C(C1=CC=C(OC2=CC=CC=C2)C=C1Cl)C3=CNC4=NC=NC(N[C@H]5CO[C@H](CO)CC5)=C43
|
InChi Key |
JSFCZQSJQXFJDS-QAPCUYQASA-N
|
InChi Code |
InChI=1S/C25H23ClN4O4/c26-21-10-17(34-16-4-2-1-3-5-16)8-9-19(21)23(32)20-11-27-24-22(20)25(29-14-28-24)30-15-6-7-18(12-31)33-13-15/h1-5,8-11,14-15,18,31H,6-7,12-13H2,(H2,27,28,29,30)/t15-,18+/m1/s1
|
Chemical Name |
(2-chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone
|
Synonyms |
ARQ531; MK1026; ARQ-531; MK-1026; ARQ 531;
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~104.40 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0880 mL | 10.4399 mL | 20.8799 mL | |
5 mM | 0.4176 mL | 2.0880 mL | 4.1760 mL | |
10 mM | 0.2088 mL | 1.0440 mL | 2.0880 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.